Connect Biopharma Holdings (CNTB) Change in Accured Expenses (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted quarterly Change in Accured Expenses of -$404000.0 for Q1 2026, up 28.37% year-on-year from -$314718.2 in Q1 2025, and down 118.13% on a QoQ basis from $2.2 million in Q4 2025.
Connect Biopharma Holdings (CNTB) Change in Accured Expenses (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings (CNTB) has reported Change in Accured Expenses for 3 consecutive years, with -$404000.0 the latest figure, recorded in Q1 2026.
- Quarterly Change in Accured Expenses rose 28.37% year-over-year to -$404000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 218.61% YoY) and the FY2025 annual result came in at $3.4 million, up 300.24% from the prior year.
- Change in Accured Expenses slipped to -$404000.0 in Q1 2026 per CNTB's latest filing, from $2.2 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for CNTB reached as high as $2.2 million in Q4 2025 and fell as low as -$1.3 million in Q2 2024.
- A 3-year average of $141888.9 and a median of -$82000.0 in 2024 frame the typical range for Change in Accured Expenses.
- The largest YoY upside for Change in Accured Expenses was 1318.29% in 2025 against a maximum downside of 177.79% in 2025.
- Year by year, Change in Accured Expenses stood at -$1.0 million in 2024, then jumped by 319.29% to $2.2 million in 2025, then plunged by 118.13% to -$404000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$404000.0, $2.2 million, and $999000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Connect Biopharma Holdings | 120.44 Mn | 120.44 Mn | - | -404,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -404,000.00 |
| Mar 31, 2026 | -404,000.00 |
| Dec 31, 2025 | 2.23 Mn |
| Dec 31, 2025 | 2.23 Mn |
| Sep 30, 2025 | 999,000.00 |
| Sep 30, 2025 | 999,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Jun 30, 2025 | 695,000.00 |
| Mar 31, 2025 | -564,000.00 |
| Mar 31, 2025 | -564,000.00 |
| Dec 31, 2024 | -1.02 Mn |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -82,000.00 |
| Sep 30, 2024 | -82,000.00 |
| Jun 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Mar 31, 2024 | 725,000.00 |
| Mar 31, 2024 | 725,000.00 |